Apricus Biosciences' CEO Sees Higher Revenue if Pfizer Inc. Viagra(R) Litigation is Successful

SAN DIEGO, June 17, 2011 (GLOBE NEWSWIRE) -- Dr. Bassam Damaj, the Chairman, President and Chief Executive Officer of Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) (http://www.apricusbio.com) noted today his belief that the specialty biopharmaceutical company could see higher revenues should Pfizer, Inc. ("Pfizer") be successful in its patent litigation battle against the introduction of generic versions of its Viagra® product for the treatment of erectile dysfunction ("ED").